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Abstract
Septic shock is a major cause of death following trauma and is a persistent problem in surgical patients throughout the
world. It is characterised by hypotension and vascular collapse, with a failure of the major organs within the body. The role
of excessive nitric oxide (NO) production, following the cytokine-dependent induction of the inducible nitric oxide synthase
(iNOS), in the development of septic shock is discussed. Emphasis is placed upon the signal-transduction process by which
iNOS is induced and the role of NO in cellular energy dysfunction and the abnormal function of the cardiovascular system
and liver during septic shock. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Sepsis and septic shock
Sepsis is de¢ned as the systemic response to infec-
tion, the most common cause being the contamina-
tion of the blood with bacteria [1]. Septic shock (sep-
sis with hypotension) develops in almost half of the
patients as a complication, with a mortality rate of
40^60%, despite treatment [2^5]. The development of
shock results in a progressive failure of the circula-
tion to provide blood and oxygen to vital organs of
the body resulting in impaired tissue perfusion and
oxygen extraction [4]. The key symptoms include a
severe fall in blood pressure (hypotension) with hy-
poreactivity to vasoconstrictor agents (vasoplegia)
which may lead to the dysfunction or failure of ma-
jor organs including lungs, liver, kidneys and brain
(multiple organ dysfunction, MODS) and ultimately
death [2^5].
Although the most common cause of septic shock
is secondary to Gram-negative infections (endotoxic
shock), invasion of Gram-positive organisms ac-
counts for an increasing percentage of cases (1/3 to
1/2 of all incidences) with viruses, fungi and parasites
accounting for a small number of cases [1]. Individ-
uals may be predisposed to septic shock following
impairment of the host defence mechanisms, for ex-
ample, following trauma, burn injuries, diabetes, cir-
rhosis and treatment with immunosuppressive and
chemotherapeutic agents [1,2].
Septic patients are in a hyperdynamic state char-
acterised by tachycardia, high cardiac output, low
systemic vascular resistance, hypoxaemia, oliguria
and lactic acidosis [4,5]. Following infection there is
an increase in the circulating concentrations of cat-
echolamines, cortisol and glucagon [2] resulting in
tachycardia and peripheral vasoconstriction. This
phase is followed by a progressive vasodilation asso-
ciated with high cardiac output and decreased vascu-
lar resistance and in some cases vasoplegia. Subse-
quent to this, cardiac failure develops with a
progressive fall in cardiac output and marked disturb-
ances in tissue perfusion and oxygenation occur [4].
Hyperglycaemia is commonly present and represents
the in£uence of circulating cytokines and glucoregu-
latory hormones; however, in advanced stages hypo-
glycaemia may occur due to depletion of hepatic gly-
cogen and inhibition of gluconeogenesis ([6] and
references therein). There are also associated marked
increases in plasma transaminase activity, urea and
bilirubin concentrations, indicative of hepatic and
renal injury, while the development of lactic acidosis
re£ects inadequate tissue perfusion and anaerobic
metabolism [2].
It is now clearly established that bacterial endotox-
in, a lipopolysaccharide (LPS) component of the out-
er membrane of Gram-negative bacteria, is the major
mediator of the high morbidity and mortality rates
characteristic of Gram-negative septic shock. Admin-
istration of endotoxin experimentally to animals
mimics the symptoms of septic shock, while infusion
in man results in a hyperdynamic, hypermetabolic
response similar to that of shock due to Gram-neg-
ative bacteraemia. The morbidity and mortality in
septic patients and animals can be decreased by
treatment with antibodies to endotoxin (reviewed in
[2]). The structure of the endotoxin complex is shown
in Fig. 1. In Gram-positive shock, a variety of medi-
ators have been proposed [2] ; however, it is evident
that the peptidoglycan and lipoteichoic acids (LTA)
of the cell wall (Fig. 1) are important mediators (re-
viewed in [3]). Both the peptidoglycan and LTA syn-
ergise to produce the characteristic features of septic
shock, MODS and ultimately death in rodent models
[3,7]. These e¡ects are not observed with either LTA
or peptidoglycan alone, although high doses of LTA
can cause circulatory failure but not MODS [7,8].
Gram-positive bacteria may also release other entero-
toxins and exotoxins, for example toxic shock syn-
drome toxin 1, which are involved in the pathogen-
esis of sepsis (reviewed in [1]).
The presence of products of bacterial origin in the
bloodstream leads to the release of endogenous cy-
tokines which are responsible for the development of
septic shock. Patients with septic shock display in-
creased levels of TNF-K, IL-1L, IFN-Q and IL-6 in
their serum, the latter showing a positive correlation
with fatal outcome [5]. Administration of LPS to
rabbits triggers a sequential release of TNF-K, IL-
1L and IL-6 [9], while peptidoglycan and LTA syner-
gise to cause release of TNF-K and IFN-Q in the rat
[7] and TNF-K and IL-6 production by monocytes in
vitro [10]. TNF-K and IL-1L alone reproduce the
systemic and pathological e¡ects of septic shock in
animals and man [11,12], while animals pretreated
with anti-TNF-K antibodies or IL-1L receptor antag-
onists are protected against shock, although they are
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without e¡ect once shock has developed [5,13]. Mice
in which the gene for the TNF-K receptor, TNF-
KRp55, has been disrupted are also resistant to en-
dotoxic shock, although TNF-K does not induce le-
thality by itself. LPS-induced lethal toxicity requires
the synergistic e¡ect of TNF-K, IL-1L, IFN-Q and
NO ([13] and references therein).
2. Nitric oxide and septic shock
Nitric oxide (NO) is a free radical generated by a
family of enzymes, the NO synthases (NOS), by the
oxidation of one of the guanidino nitrogen atoms of
L-arginine to form NO plus citrulline. This is associ-
ated with the oxidation of 1.5 molecules of NADPH
per molecule of NO produced and the reduction of
molecular oxygen. The reaction sequence involves
the generation of an Ng-hydroxy-L-arginine inter-
mediate and water, followed by the oxidation of
Ng-hydroxy-L-arginine in presence of molecular oxy-
gen to form NO, L-citrulline and water [14,15]. There
are at least three di¡erent isoforms of NO synthase
in mammalian cells : endothelial NOS (eNOS or
NOS III) found in endothelial cells, epithelial cells
and cardiac myocytes; neuronal NOS (nNOS or
NOS I) found in neuronal cells and skeletal muscle,
and inducible NOS (iNOS or NOS II) found in mac-
rophages, hepatocytes, smooth muscle and a variety
of other tissues. All NOS enzymes contain several
cofactors in their active form ^ calmodulin, £avin
adenine dinucleotide, £avin mononucleotide and tet-
rahydrobiopterin [14,16]. eNOS and nNOS are ex-
pressed constitutively and are activated by an in-
crease in intracellular Ca2 and are involved in
regulating vascular tone [17,18] and neurotransmis-
sion [17] respectively, whereas iNOS is functionally
Ca2-independent and involved in the immune de-
fence [16,17], although it is expressed in many cell
types following endotoxin or pro-in£ammatory cyto-
kine treatment [14^16,19]. nNOS and eNOS are
thought to produce small Ca2-dependent bursts of
NO formation, whereas expression of iNOS results in
sustained production of large quantities of NO which
are postulated to mediate the alterations in the vas-
cular system and the tissue damage apparent in sep-
tic shock and MODS.
In recent years there has been a plethora of pub-
lications implicating the overproduction of NO in the
pathophysiology of septic shock and MODS and the
induction of NO synthase, with the consequent ex-
cessive formation of NO, has been proposed to be a
major factor involved in the pathologic vasodilata-
tion and tissue damage observed [3^6,18]. It is evi-
dent that nitrate production is increased in endotox-
aemia and that plasma and urinary nitrite and nitrate
concentrations are elevated in patients with sepsis
and septic shock, the level increasing with the pres-
ence of shock and in patients with MODS ([20] and
references therein). The only known source of nitrite
and nitrate production in mammalian tissues is
through the conversion of L-arginine to NO by the
NO synthases and subsequent degradation of NO
into nitrite and nitrate, the stable end products of
Fig. 1. The structure of LPS and lipoteichoic acid. The endo-
toxin (LPS) complex is composed of three functionally distinct
regions: the outermost region consisting of multiple polysac-
charide units that form the speci¢c bacterial O-antigens; the in-
ner and outer core region; and the lipid A component linking
the endotoxin molecule to the bacterial outer membrane. The
majority of the toxicity is considered to reside in the lipid A
component. The lipoteichoic acids are poly(glycerophosphate)
chains with position 2 of the glycerophosphate substituted in
part with either D-alanine ester or D-alanine ester and glycosyl
residues such as D-glucose, D-galactose and N-acetyl-D-glucos-
amine. It is anchored in the plasma membrane and extends to
the surface of the cell wall.
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NO metabolism [17]. There is a quantitative and
qualitative clinical relationship between NO produc-
tion, endotoxaemia, haemodynamic dysfunction and
MODS in human septic shock [20].
iNOS is induced in a variety of tissues in endotox-
aemia [17,19] (see Fig. 2) and is proposed to be part
of an adaptive response of the host defence mecha-
nism directed towards limiting tissue injury and in-
fections. Once expressed, the inducible enzyme of
activated macrophages is capable of producing high
concentrations of NO over long periods which has
both bactericidal and tumouricidal e¡ects [17].
During endotoxaemia iNOS expression and in-
creases in iNOS mRNA and protein have been ob-
served in a variety of cell types including endothelial
cells, macrophages, Kup¡er cells, hepatocytes, vascu-
lar smooth muscle cells, kidney cells, chondrocytes,
cardiac myocytes, pancreatic islets and ¢broblasts
[15^17,19]. Similarly in the Gram-positive model of
sepsis, LTA alone or in combination with peptido-
glycan induces iNOS activity and protein in vascular
smooth muscle cells and macrophages in vitro and
the lung, aorta, heart, liver, pancreas and kidney in
vivo [7,21,22]. Although peptidoglycan does not in-
duce iNOS in cultured macrophages, it synergises
with LTA in causing the expression of iNOS protein
and activity in vitro and in the rat in vivo [7].
The speci¢c factors which induce iNOS in septic
shock vary between tissues; however, they include
microbes, microbial products and proin£ammatory
cytokines and there is strong synergy between agents.
For example, in murine macrophages LPS induces
iNOS and strongly synergises with IFN-Q, whereas
in cultured hepatocytes LPS alone has no e¡ect,
but enhances the induction by IL-1L, TNF-K and
IFN-Q, with a maximal response being observed
with a combination of IL-1L, TNF-K and IFN-Q
plus LPS [23,24]. Similarly, while IL-1L enhances
iNOS expression in chondrocytes, smooth muscle
cells, hepatocytes and islets of Langerhans, it has
no e¡ect in macrophages [25].
The relevance of overproduction of NO to the de-
velopment of endotoxic shock has been demon-
strated by the use of NO synthase inhibitors and
agents which block the expression of iNOS. Admin-
istration of Ng-methyl-L-arginine (L-NMMA) in both
animal models and man with septic shock has been
demonstrated to restore blood pressure and reverse
the endotoxin-induced hypotension and hyporespon-
siveness to vasoconstrictor agents [5]. In addition
NOS inhibitors have been shown to improve renal
and hepatic function following either endotoxin
treatment or treatment with LTA and peptidoglycan
[26^28] and increase survival rates in animal models
of septic shock [5] (but see later). The hypotension
and early mortality caused by endotoxin is also atte-
nuated in iNOS-de¢cient mice, suggesting that while
the enhanced formation of NO by iNOS defends the
body against infectious agents and tumour cells, ex-
cessive induction of iNOS in other tissues (e.g. vas-
culature) may cause shock and ultimately tissue dam-
age [29]. Further it is now well established that the
expression of iNOS in response to LPS and LTA is
negatively regulated by dexamethasone in vivo
[30,31] and endogenous glucocorticoids and an in-
crease in the plasma levels of steroids has been pro-
posed to contribute to the development of cardiovas-
cular tolerance to repetitive injections of LPS [31].
Similarly pretreatment of rats with dexamethasone
prevents the LPS- and LTA-induced induction of
iNOS and attenuates the circulatory failure and hy-
poreactivity to vasoconstrictor agents [8,31], further
Fig. 2. Western blot analysis of iNOS in tissues in the endotoxin-treated rat. Rats were injected with LPS (4 mg/kg) and the tissues
removed after 6 h. 40 Wg of protein was used from each tissue and analysed for iNOS expression by Western blotting. Control rats
showed no signi¢cant iNOS expression in any tissue. He, heart; Du, duodenum; Sp, spleen; Di, diaphragm, Th, thymus; Ki, kidney;
Il, ileum; Lu, lung; Li, liver.
BBABIO 44744 26-4-99
M.A. Titheradge / Biochimica et Biophysica Acta 1411 (1999) 437^455440
supporting the concept that excess NO production
accounts for circulatory failure in septic shock.
Experiments using agents directed against cyto-
kines or knockout mice generally support a role for
the involvement of iNOS in sepsis ([32] and referen-
ces therein). Pretreatment of animals with the IL-1L
receptor antagonist has been demonstrated to attenu-
ate the induction of iNOS in rats and ameliorate the
delayed hypotension and tachycardia in response to
endotoxin and the hyporeactivity to norepinephrine
in aorta ex vivo [25,32]. Similarly administration of
anti-TNF-K antibodies prevents the onset of septic
shock during lethal bacteraemia and anti-TNF-K
antibody or soluble TNF-KR antagonist is able to
partially block LPS-induced pulmonary and hepatic
NOS expression [32]. Experiments using TNF-KR1
knockout mice have con¢rmed that TNF-K is in-
volved in iNOS expression; however, this may not
be the case for all tissues as it is evident in liver but
not spleen [32]. The use of monoclonal antibodies to
IFN-Q also partially protects against iNOS expres-
sion and mortality, while disruption of the IFN-Q
gene indicates that endogenous IFN-Q is required
for both the LPS-induced iNOS expression and in-
crease in serum nitrate plus nitrite, although again
the extent of the involvement of IFN-Q in the induc-
tion of iNOS is tissue dependent [32].
Recent work indicates that not only is iNOS
mRNA induced in liver after endotoxin or LTA
treatment of the rat, but eNOS (NOSIII) mRNA
expression is also increased to an even larger extent
[22]. The signi¢cance of this during septic shock re-
mains to be established as it is not evident in kidney
[22] and eNOS is down-regulated in vascular epithe-
lium under these conditions [5].
3. The mechanism of iNOS induction in septic shock
The expression of iNOS by LPS, LTA and cyto-
kines results from the interaction of LPS, LTA, pep-
tidoglycan, IL-1L and TNF-K with receptors on the
plasma membrane, resulting in a signal being trans-
ferred to the gene. LPS interacts with a speci¢c LPS
binding protein (LBP) and this complex interacts
with cell surface molecule CD14 [33]. Recent evi-
dence suggests that the signal may be transduced
across the membrane via the Toll-like receptor-2
[34]. Signalling via peptidoglycan has also been sug-
gested to occur through CD14 [35]. IL-1 and TNF
each occur in two forms, K and L. TNF-K and both
forms of IL-1 are made by activated monocytes and
macrophages, whereas TNF-L is made by activated T
lymphocytes (reviewed in [36]). There are two recep-
tors for both IL-1 and TNF and the two forms of
each cytokine interact with the same receptors. IL-1K
and L interact with the type 1 IL-1 receptor for signal
transduction, whereas type II does not appear to
transmit any signal and functions as an inhibitor of
IL-1 action [36]. The two types of TNF receptor, p55
(type I) and p75 (type II) have di¡erent end e¡ects,
the p55 receptor signals the in£ammatory response
and apoptosis, whereas p75 mediates the proliferative
actions of TNF-K [36].
Although the precise signal transduction pathway
for iNOS induction and the development of septic
shock and MODS remains to be established, it is
evident that tyrosine kinase activation is involved
in both the secretion of the cytokines and the signal
transduction pathway following interaction of the
cytokine with its receptor at the target cell. The ty-
rosine kinase inhibitors, tyrphostin AG 126, genistein
and erbstatin, can prevent LPS-induced lethal toxic-
ity in mice [13] and have also been reported to pre-
vent the circulatory failure (hypotension and vascu-
lar hyporeactivity) caused by endotoxin in vivo [37].
Liver injury, pancreatic injury, lactic acidosis and
hypoglycaemia are also attenuated by preventing ty-
rosine phosphorylation in the rat model of endotoxic
shock, although the renal failure is not reversed [37].
Both tyrphostins and genistein prevent the rise in
serum TNF-K [37] and TNF-K production in macro-
phages [13], together with the expression of iNOS in
response to endotoxin and cytokines in a variety of
tissues [13,37]. These agents therefore have a dual
role in preventing both cytokine release and blocking
the cytokine signalling pathway. The signal transduc-
tion pathway leading to the LTA-dependent iNOS
expression in J774.2 macrophages is also dependent
on tyrosine kinases activity [21].
Fig. 3 shows the proposed mechanism by which
these cytokines may act. It is evident that the major
response is via activation of the mitogen-activated
protein kinase (MAPK) family of proteins with sub-
sequent activation of transcription factors required
for the expression of iNOS and other genes [36,41^
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44]. There are a number of groups of MAP kinases
in mammalian cells which have been postulated to be
activated by cytokines: the extracellular signal regu-
lated kinases (MAPK1 and 2/ERK1 and 2); the c-
Jun NH2-terminal kinases (SAPK1/JNKs) and the
p38 MAP kinase family (SAPK2, 3 and 4). The ac-
tivity of these kinases is regulated by dual phospho-
rylation within the protein kinase subdomain VIII by
a kinase cascade consisting of a MAP kinase kinase
and a MAP kinase kinase kinase (Fig. 3). The im-
portance of the extracellular signal regulated kinase
cascade in septic shock is currently unclear, as
although IL-1L and TNF-K can activate MAPK1
and MAPK2 in a variety of cells via activation of
MKK1 and c-Raf (reviewed in [36]) and LPS and
peptidoglycan can strongly activate MAPK1 and
MAPK2 in RAW264.7 macrophages, this is not uni-
versally found [36] and the relevance of this pathway
may be tissue dependent. In contrast, the stress acti-
vated protein kinases appear to be the major path-
way for stimulation [42].
TNF-K and IL-1L are potent activators of the pro-
line-directed Ser/Thre SAPK1 class, a family of pro-
tein kinases which are potent c-Jun kinases [41,43].
For example, IL-1L and TNF-K activate SAPK1a
(JNK2) and SAPK1c (JNK1) in human glomerular
mesangial cells, under conditions where no e¡ects on
MAPK1 or 2 are observed and LPS alone is ine¡ec-
tive [45]. SAPK1 is activated under cell stress condi-
tions by phosphorylation on tyrosine and threonine
residues by two kinase kinases, SKK1 (SEK1/
MKK4/SAPKK1) and SKK4 (MKK7/SAPKK4/5)
[44,49]. SKK4 appears to be speci¢c for SAPK1,
and in epithelial Kb cells at least, is the major medi-
ator in the response to IL-1L and TNF-K, SKK1
being unresponsive to proin£ammatory cytokines
but not other forms of cell stress [47]. In vitro
SKK1 functions as a dual functional kinase activat-
ing both SAPK1 and SAPK2; however, it appears to
be ine¡ective in activating SAPK2 in vivo [42]. Both
SKK1 and SKK4 are subject to phosphorylation and
activation in situ and in vitro by the serine/threonine
kinase MEKK1, although two further MEKK activ-
ities have been described which activate both the
SAPK1 and MAPK pathways, MEKK2 and
MEKK3 [41^44]. MEKK2 preferentially activates
SKK1 and the SAPK1 family, while MEKK3 shows
preference for MKK1 and the MAPK pathway [49].
Other MEKK-like activities have been found such as
MUK which can also act as regulators of the SAPK1
pathway; however, the relative importance of these
di¡erent components is unclear and may well vary
from tissue to tissue, cellular distribution and activat-
ing agent. The SAPK1 pathway can also be activated
in an SKK1-dependent manner by TNF-K activating
the germinal centre kinase (GCK) independently of
Fig. 3. Signal transduction pathway for LPS, LTA, TNF-K and IL-1L. The nomenclature is based upon that of Cohen [44]. MAPK,
mitogen-activated protein kinase; SAPK, stress-activated protein kinase; MKK, MAPK kinase; SKK, SAPK kinase; Mnk, MAPK-
interacting kinase; MAPKAP-K, MAPK-activated protein kinase; NIK, NF-UB inducing kinase; IKK, IUB kinase; CPK, ceramide-
dependent protein kinase; GCK, germinal centre kinase; SMAase, sphingomyelinase.
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any activation of SAPK2 or MAPK [41,43]. SAPK1
activation results in phosphorylation and trans-acti-
vation of the transcription factors c-Jun, Elk-1, and
ATF-2 [41,42].
The second stress activated protein kinase group,
SAPK2a (p38) and 2b (p38L), has also been shown
to be phosphorylated on tyrosine and activated in
response to LPS in macrophages and other tissues,
while the novel in£ammatory drugs, CSAIDS (cyto-
kine-suppressive anti-in£ammatory drug), have been
shown to have a protective role in the endotoxic
shock model and inhibit LPS-induced TNF-K and
IL-1L production by inhibiting SAPK2a and
SAPK2b activity [36,42], suggesting the involvement
of SAPK2 in cytokine release. SAPK2 has also been
implicated in IL-6 production [46]. Like SAPK1,
SAPK2a is activated by dual phosphorylation on
Tyr and Thre residues by SKK2 (MKK3) and
SKK3 (MKK6), while SAPK2b is activated only
by SKK3 (reviewed in [41,43,44,49]). Activation of
SKK2 and SKK3 has been suggested to occur via
the protein kinase TAK-1, which may itself be regu-
lated by two binding proteins, TAB1 and TAB2 [49].
Stimulation of the SAPK2 kinases culminates in
phosphorylation of the serine kinases, MAPKAP
kinase-2 and MAPKAP-kinase-3 leading to activa-
tion and HSP25/HSP27 phosphorylation. MAP-
KAP-kinase-2 also phosphorylates CREB and
ATF-1 [41^43] and therefore SAPK2s are capable
of switching on genes whose promoters contain
CRE elements or are sensitive to homo/heterodimers
of the CREB/ATF and AP-1 families. Other physio-
logical substrates are Elk1, SAP1, CHOP, MEF2C,
MAPK-interacting protein kinase-1 (Mnk1 and
Mnk2) [41,43,44,47]. Recently a further two members
of the SAPK family have been identi¢ed which are
activated in response to IL-1L and TNF-K, SAPK3
and SAPK4 [44,47,48].
The upstream signalling mechanism for the activa-
tion of the stress activated kinase cascades in re-
sponse to endotoxin and cytokines is still not estab-
lished; however, the Rho family of GTPases, Rac1
and Cdc42Hs have been demonstrated to be involved
in the activation of SAPK1 and 2 [43,47]. It is sug-
gested that Rac/Cdc42Hs and SAPKs are coupled
via the PAK family of proteins (p21 activated kin-
ases) (PAKs 1^3). PAK-1 is activated by binding to
the GTP bound form of Rac/Cdc42Hs and can in-
duce activation of SAPKs [43]. How activation of
these kinases leads to activation of stress activated
kinases remains to be established; however, com-
plexes of GTP-Cdc42Hs, PAK and MEKK1 have
been demonstrated and in yeast, the PAK equivalent
has been shown to activate the MEKK1 homologue.
[49].
A further signalling mechanism proposed for both
TNF-K and IL-1L is via the rapid breakdown of
plasma membrane and subcellular membrane sphin-
gomyelin by a variety of sphingomyelinases to gen-
erate ceramide [43,50^53]. Exogenously applied ce-
ramide to cells or hydrolysis of sphingomyelin with
sphingomyelinase results in activation of a ceramide-
dependent serine/threonine kinase and a protein
phosphatase 2A-like activity which mimics many of
the e¡ects of TNF-K and IL-1L, e.g. activation of
stress activated kinases and MAPK activity, apopto-
sis, generation of ROIs, NF-UB translocation to the
nucleus [50^52], and the dose-dependent relaxation
of phenylephrine-contracted endothelium-denuded
rat aortic rings [53]. It is suggested to couple to
MAPK, SAPK1 and SAPK2 via activation of ceram-
ide-dependent protein kinase.
The promoter-regulatory region of both the mouse
and human iNOS genes contains a variety of possible
regulatory sequences through which iNOS expression
may be stimulated, including NF-UB, AP-1, NF-IL-
6, interferon response elements, Q-activated sites and
TNF-K-response elements. In macrophages, LPS in-
ducibility of iNOS is dependent upon the NF-UB
sequence and activation of NF-UB [16], while sup-
pression of NF-UB activation in vivo prevents the
induction of iNOS and the deleterious e¡ects of en-
dotoxin on blood pressure, responsiveness to vaso-
constrictor agents, blood glucose and tissue damage
[38]. The synergistic action of IFN-Q in iNOS induc-
tion depends upon the interaction of interferon reg-
ulatory factor-1 with the interferon-regulatory bind-
ing factor site (reviewed in [39]); however, this may
be tissue dependent as in murine macrophages IFN-Q
has been reported to cause accumulation of mRNA
in the absence of an e¡ect on the basal rate of iNOS
transcription, suggesting it may stabilise the mRNA
in addition to its transcriptional role [16]. Although
activation of the NF-UB site is important for iNOS
expression in other tissues, binding sites for other
transcription factors in the downstream portion of
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the iNOS 5P-£anking sequence are also critical for
iNOS induction [40].
The mechanism by which iNOS expression
through activation of NF-UB links to LPS and cyto-
kines has recently been described (reviewed in [54]).
In unstimulated cells, NF-UB is retained in the cyto-
plasm in an inactive complex with the inhibitory IUB
proteins. TNF-K-induced trimerisation of the
TNFR1 receptor results in recruitment of the
TNFR-associated death-domain protein (TRADD),
the TNFR-associated factor-2 (TRAF-2) and the ser-
ine/threonine kinase, receptor-interacting protein
(RIP). TRAF-2 binds to a further serine/threonine
MAP kinase kinase kinase family member, NF-UB
inducing kinase (NIK), which itself associates with
a complex of two further kinases, IUB kinase
(IKK) K and L, initiating a kinase cascade leading
to the phosphorylation of the IUB proteins. There is
evidence to suggest that IKKK is preferentially phos-
phorylated and activated by NIK [55], whereas
MEKK1 has been postulated to preferentially phos-
phorylate and stimulate IKKL activity [56]. Phos-
phorylation of the IUB proteins by either of the
IKKs leads to polyubiquitination and subsequent
degradation of IUBs [54^56]. Degradation of IUB re-
leases NF-UB and allows the NF-UB to translocate to
the nucleus to activate its target genes [54]. Evidence
suggests that IL-1 also activates NF-UB via a similar
mechanism [54]. IL-1 induces the formation of a
complex consisting of the IL-R1 receptor, an acces-
sory protein, AcP, the serine/threonine kinase protein
kinase IRAK, and a TRAF protein, TRAF-6. Like
TRAF-2, TRAF-6 can also interact with NIK and
activate the kinase cascade. TNF-K and IL-1L have
also been proposed to activate NF-UB via stimula-
tion of acidic sphingomyelinase and generation of
ceramide [51,52]; however, the importance of this
route has been questioned (reviewed in [52]).
Although it is evident that activation SAPK2 (p38)
is involved in the LPS-induced release of TNF-K and
IL-1L and both TNF-K and IL-1L activate SAPK2
(p38) and NF-UB, the role of the SAPK2 arm of the
signal transduction pathway in NF-UB activation
and iNOS expression is to be questioned. In addition
to cytokines, arsenite and osmotic stress both po-
tently activate SAPK2 in 293 cells ; however, neither
leads to NF-UB activation [57]. Similarly while nu-
merous studies have demonstrated that antioxidants
abolish iNOS expression and NF-UB activation
([57,58] and references therein), they are reported to
activate SAPK2 and AP-1 [57]. Recent studies indi-
cate that SAPK2 activation occurs via TRAF-2, but
that it is independent of NIK and NF-UB activa-
tion[59]. It is suggested that while it is a crucial me-
diator in TNF-induced activation of NF-UB-depend-
ent gene expression, it is not involved in increasing
NF-UB activation and translocation to the nucleus,
but is important for the transcriptional activation by
modulating the transactivation capacity of the NF-
UB p65 subunit [59,60]. In contrast to this, the work
of Guan et al. has suggested that in rat glomerular
mesangial cells, IL-1L activates iNOS expression and
mRNA production, while at the same time it acti-
vates SAPK2, which acts as a negative regulator of
iNOS expression [61], suggesting that the level of
expression of iNOS may be dependent on the balance
between the di¡erential activation of the SAPK1 and
2 pathways within di¡erent tissues with di¡erent
stimulants.
4. Inhibition of iNOS expression in endotoxic shock
While it is clear that IL-1L, IL-6, TNF-K and IFN-
Q play a role in the induction of iNOS during septic
shock, it is evident that a variety of anti-in£amma-
tory cytokines and other agents are also expressed
which are able to antagonise this induction process
[4,15]. For example, glucocorticoids are known to be
elevated during sepsis and these can almost com-
pletely inhibit iNOS expression in a wide variety of
cell types exposed to LPS, LTA or cytokines [4,15].
Dexamethasone is suggested to inhibit iNOS expres-
sion by the activated glucocorticoid receptor prevent-
ing the binding of NF-UB, but not AP-1, to the NOS
II promoter, thereby preventing transcription [62].
Blocking NF-UB activation and iNOS expression
by dexamethasone ameliorates the hypotension, hy-
poresponsiveness to vasoconstrictor agents, hypogly-
caemia, lactic acidemia and liver and pancreatic in-
jury [38]. Similarly cytokines such as TGF-L, IL-4,
IL-8, IL-10 and macrophage deactivating factor are
capable of suppressing iNOS activity (reviewed in
[4,5]). Evidence suggests that TGF-L reduces cyto-
kine-induced iNOS activity by both inhibiting
mRNA translation, decreasing its stability and in-
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creasing iNOS protein degradation, whereas IL-4 in-
terferes with iNOS transcription [15,16].
The interaction of hormones which act via cAMP
and agents which elevate cAMP is complex and tis-
sue dependent. In vascular smooth muscle cells, rat
mesangial cells, peritoneal macrophages and cardiac
myocytes, an elevation of cAMP synergises with cy-
tokines to increase the induction of iNOS (see [63]
for references) and indeed an activation of protein
kinase A has been demonstrated to be essential for
iNOS expression by IL-1L in neonatal cardiac myo-
cytes [64]. In contrast, in astrocytes and hepatocytes
[63,65] NO production is diminished by elevating cy-
clic AMP with glucagon or forskolin. The latter oc-
curs via a reduction in the rate of transcription and
translation of the iNOS gene [63,65]. The physiolog-
ical signi¢cance of this remains to be established;
however, it is evident that a major feature of both
sepsis and endotoxin administration to animals is
hyperglucagonaemia and a decrease in the plasma
insulin:glucagon ratio [63]. A recent study has indi-
cated that treatment of rats with dibutyryl cAMP
can increase blood £ow through the liver, reduce
the serum concentration of TNF-K, prevent liver ne-
crosis and acute hepatic failure and increase survival
following endotoxin treatment of galactosamine-sen-
sitised animals [66]. Preliminary experiments in our
laboratory have also demonstrated that glucagon
pretreatment of rats results in a reduction of the
endotoxin-induced increases in serum NO32 +NO
3
3
concentrations, gives a partial inhibition of hepatic
iNOS induction and completely eliminates hepatic
damage as judged by release of lactate dehydrogen-
ase and aspartate aminotransferase activity, suggest-
ing that an elevation of circulating concentrations of
glucagon and steroids may help to limit tissue dam-
age during sepsis. Elevating cAMP by isoproterenol
administration has similarly been shown to block
LPS-induced TNF-K secretion, increase circulating
concentrations of IL-10 and IL-6 and reduce NO
formation in mice [67]. In the same study, treatment
of anaesthetised rats with isoproterenol prevented the
endotoxin-induced hyporeactivity to norepinephrine
suggesting an elevation of cAMP may be bene¢cial
at multiple sites within the pathway. The mechanism
by which cAMP exerts this negative e¡ect on iNOS
expression has not been established; however, cAMP
and forskolin have been reported to inhibit SAPK1c
activity and c-Jun expression and AP-1 activation in
vascular smooth muscle [68].
5. NO and energy transduction in septic shock
Severe sepsis is characterised by a progressive fail-
ure of energy metabolism and a marked decrease in
tissue oxygen extraction, resulting in tissue hypoxia
and increased venous oxygen concentration in both
septic patients and animal models [69]. Taken togeth-
er with the lactic acidosis and acidemia, this suggests
an impairment of oxygen utilisation, although this
may also be caused by tissue hypoperfusion [2,69].
A number of studies, particularly using the endotoxic
model of shock, have demonstrated an inhibition of
respiration in liver, heart, skeletal muscle, kidney and
brain; however, this has not been universally found
and mitochondrial respiration has been reported to
be either inhibited, unchanged or even stimulated
during sepsis (reviewed in [69^71]). It is likely that
the predominant e¡ect on mitochondrial metabolism
depends upon a number of factors including the
method of inducing shock, whether by endotoxin
or caecal ligation and perforation, the time period
over which sepsis is induced, the dose of the inducing
agent and the species.
Numerous studies have indicated that authentic
NO or induction of iNOS in tissues by LPS or cyto-
kines is accompanied by an inhibition of respiratory
chain activity and accumulation of lactate. This has
been demonstrated in vascular smooth muscle cells,
hepatocytes, macrophages, astrocytes and cardiac
myocytes (reviewed in [72]). It is now evident from
studies using intact cells and isolated mitochondria
that physiological levels of NO interact competitively
with oxygen at cytochrome oxidase (complex IV) re-
versibly inhibiting O2 consumption [72]. The ability
of NO to inhibit cytochrome oxidase and ATP syn-
thesis therefore will be greater in areas of low oxygen
tension (i.e. physiological O2 conditions) and may be
exacerbated in shock if there is redistribution of
blood £ow away from highly metabolic areas, com-
promising oxygen availability. An inhibition of cyto-
chrome oxidase also increases the production of re-
active oxygen intermediates (H2O2 and O32 ) by the
mitochondrial respiratory chain which may lead to
irreversible damage as a result of the NO interacting
BBABIO 44744 26-4-99
M.A. Titheradge / Biochimica et Biophysica Acta 1411 (1999) 437^455 445
with the O32 to form peroxynitrite (OONO
3) [73].
Initial studies suggested that NO directly damages
iron-sulphur centres in the mitochondrial electron
transport chain; however, it is now evident that these
centres are relatively insensitive to NO and that long
term exposure to NO irreversibly inhibits complexes
I, II, the ATPase and possibly III, but not complex
IV as result formation of peroxynitrite (see [72] for
references). Mitochondrial aconitase is also inhibited
under these conditions resulting in an inhibition of
both TCA cycle activity and respiration [74]. There is
also potential for OONO3 formation to be further
enhanced by NO interacting with the haem of cata-
lase, reversibly inactivating the enzyme and prevent-
ing H2O2 breakdown, while encouraging superoxide
dismutase (SOD)-dependent OONO3 formation [72].
Peroxynitrite has also been shown to cause nitration
and inhibition of SOD, making more O32 potentially
available and setting up an autocatalytic cycle [75].
Experiments employing cell permeable SOD mimet-
ics in immunostimulated macrophages suggest a role
for both peroxynitrite-dependent and direct NO-de-
pendent mechanism in the suppression of mitochon-
drial respiration [76].
It is now established that endotoxic or septic shock
leads to substantial increase in levels of NO and bio-
logically active OONO3. It has been demonstrated in
the vicinity of large blood vessels such as thoracic
aorta, in activated macrophages, endothelial cells,
human neutrophils and in lungs of endotoxic animals
[77,78]. The inhibition of respiration in macrophages
and smooth muscle cells by OONO3 is paralleled by
DNA single strand breakage that triggers the activa-
tion of the nuclear repair enzyme, poly(ADP)ribosyl-
transferase (PARS) [78]. Activation of PARS results
in ADP-ribosylation and depletion of intracellular
NAD, which, together with the inhibition of the
respiratory chain and TCA cycle activity, is proposed
to result in decreased ATP formation and ultimately
cell death (reviewed in [78]). Over-production of NO
is also associated with inhibition of glyceraldehyde
phosphate dehydrogenase (GAPDH) by ribosylation
and nitrosylation [79,80] resulting in an inhibition of
glycolytic £ux, thus contributing to defective energy
production. The latter has been proposed to be im-
portant to tissue O2 metabolism during sepsis, and to
contribute to the contractile suppressing e¡ects of
NO in the vascular system in endotoxic shock [5].
The use of the inhibitors, 3-aminobenzamide and
nicotinamide, has demonstrated the importance of
the PARS pathway in septic shock. They are protec-
tive in the rat model of endotoxic shock and ameli-
orate the defects in cellular energy metabolism, main-
tain blood pressure by preventing loss of contractility
and reduce the degree of endothelial cell dysfunction
[78]. Inhibition of PARS activation by preventing
OONO3 formation by SOD mimetics also suppresses
the inhibition of mitochondrial respiration in macro-
phages and cultured smooth muscle cells after immu-
nostimulation and ameliorates the vascular hypo-
reactivity and endothelial dysfunction in thoracic
aorta ex vivo in endotoxin-treated rats [78].
OONO3 has also been implicated in the oxidation
of mitochondrial thiols, mixed disulphides and
NAD(P)H [81,82]. The latter has been suggested to
lead to permeability transitions and depolarisation of
the mitochondrial membrane, further compromising
ATP synthesis and ability to sequester Ca2, both of
which are suggested to contribute to necrotic cell
death or apoptotic cell death (reviewed in [81]). In
addition, other cyclosporin-sensitive pathways have
been suggested to account for alterations in Ca2
release by OONO3, possibly involving ADP-ribose,
which do not involve changes in v8 [82].
Although the above suggests that alterations in
mitochondrial function via NO or OONO3 are im-
portant in the development of cellular dysfunction
during septic or endotoxic shock, this may not be
applicable to all tissues. The initial work of Stadler
et al. indicated that exposure of hepatocytes to au-
thentic NO leads to a decrease in aconitase and com-
plex I and II activity (although not complex IV) [83].
However, in contrast, endogenously generated NO
by exposure to cytokines plus LPS or activated
Kup¡er cell supernatants results in only a minor
NO-dependent depression of mitochondrial aconitase
and no signi¢cant change in the other complexes
[83,84]. Similarly induction of septic shock and NO
synthesis by C. parvum injection into rats results in
virtually no inhibition of mitochondrial activity [84].
Subsequent studies have demonstrated that the ma-
jor inhibition of respiration in hepatocytes following
cytokine addition is due to TNF-K via an NO-inde-
pendent mechanism, possibly involving activation of
the sphingomyelinase pathway [51,85]. This suggests
that the importance of physiological concentrations
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of NO at the level of the mitochondria is tissue spe-
ci¢c and may not be relevant, particularly in tissues
such as liver which have a high capacity to metabo-
lise the NO.
6. NO and the vascular system
Excessive NO synthesis and induction of iNOS has
been implicated in the cardiovascular dysfunction
observed in both patients with septic shock and ani-
mal models of endotoxaemia (reviewed in [4,5]). It is
evident that elevated production of NO in response
to LPS, LTA and cytokines is due to an initial acti-
vation of eNOS followed by induction of iNOS re-
sulting in vasodilation and hyporeactivity to pressor
agents (epinephrine, vasopressin, angiotensin II, se-
rotonin, calcium, potassium) [4,5,18]. Interestingly
during the late phase of shock there is an impairment
of the biosynthesis of NO by eNOS in vascular en-
dothelium, the constitutive form being down-regu-
lated as the inducible form is expressed [5]. Although
iNOS induction occurs in the endothelial cells, the
most important source of NO within the vessel wall
is probably the vascular smooth muscle and iNOS
derived from the vasculature is responsible for the
excessive vasodilatation and hyporeactivity which is
characteristic of the hypotension in shock. The work
of Li et al. suggests that the level of induction of
iNOS and production of NO within the vascular sys-
tem at di¡erent anatomical sites may be variable,
resulting in di¡erent degrees of vasodilatation and
catecholamine insensitivity, with areas of underper-
fusion of metabolically active tissues and areas of
over-perfusion of areas that are not metabolically
active [86]. This may contribute to the de¢cient oxy-
gen extraction, cell hypoxia and development of lac-
tic acidosis characteristic of shock. [2].
In vivo, prevention of induction of iNOS by anti-
in£ammatory cytokines, e.g. TGF-L, glucocorticoids
or neutralisation of proin£ammatory cytokines and
lipid mediators of shock (e.g. TNF-K, IL-1L, PAF)
improves haemodynamics in shock and reduces the
hypotension and degree of vascular hyporeactivity
[5]. Similarly the vasodilatation of the smooth
muscles and the hyporeactivity can be reversed by
both non-isoform selective inhibitors of NOS and
inhibitors selective for iNOS [5] and are reduced in
iNOS-de¢cient mice [29].
Induction of iNOS is also associated with time-
dependent vascular permeability changes, indicative
of endothelial cell injury, which can be inhibited by
dexamethasone [87]. This may result from the down-
regulation of eNOS expression by pro-in£ammatory
cytokines such as TNF-K, or endothelial cell damage
due to cytotoxic e¡ects of NO as a result of iNOS
expression, OONO3 or oxygen derived radicals [88].
Excessive production of NO by iNOS has been
shown to be cytotoxic towards endothelial cells
[88], while the increased blood £ow may augment
direct injurious action on microvascular endothe-
lium. The increase in systemic microvascular perme-
ability, with loss of intravascular blood volume, may
be a major factor contributing to the decrease in
cardiac output seen in severe sepsis [2]. Inhibitors
of NOS have been demonstrated to reduce the degree
of endothelial cell dysfunction in rodent models of
endotoxic shock and can attenuate the changes in
vascular permeability and oedema formation induced
by endotoxin and proin£ammatory cytokines in a
variety of tissues including skin, jejunum, ileum and
colon (reviewed in [88]).
Excessive vasodilation in response to bacterial
products and cytokines is suggested to be due to
NO acting via both cGMP-dependent and cGMP-
independent mechanisms [5]. NO produced in both
the vascular smooth muscle and endothelial cells ac-
tivates the soluble guanylate cyclase by binding to
the haem moiety, causing an increase in cGMP for-
mation and cGMP-dependent reduction of intracel-
lular Ca2 and vascular relaxation [5,18]. Non-
cGMP-dependent mechanisms are the result of direct
e¡ects of NO or OONO3 on the vascular smooth
muscle leading to reduced contractility by energy de-
pletion, activation of Ca2-dependent K channels
and ATP-sensitive K channels [5].
Reduced myocardial performance is an important
contributing factor in shock and induction of NOS
in the myocardium has been demonstrated and pro-
posed to be responsible for cardiac dysfunction in
endotoxaemia [89]. Although induction of iNOS ac-
tivity in the heart of animals exposed to endotoxin is
relatively small when compared to other organs [19]
(Fig. 2), it is clearly established that the expression of
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iNOS in isolated rat cardiac myocytes or papillary
muscle cells exposed to TNF-K, IL-1L or macro-
phage-conditioned medium is associated with an L-
NMMA-attenuated reduction in myocardial contrac-
tility, decreased beating rate of myocytes and re-
duced inotropic response to isoproterenol (reviewed
in [5]). Infusion of isolated hearts with IL-1L and
TNF-K induces iNOS and suppresses contraction
[89], while cardiac myocytes isolated from endotoxic
rats show impaired contractility which is ameliorated
by dexamethasone and iNOS inhibitors [90]. In con-
trast, studies using Langendor¡ heart preparations
prepared from endotoxic animals, rather than car-
diac myocytes, failed to demonstrate an inhibition
of the isoproterenol-inotropic response, while pre-
treatment of the animals with Ng-nitro-L-arginine
or aminoguanidine prior to the endotoxin failed to
improve left ventricular function [91]. Despite the
fact that iNOS inhibitors were ine¡ective in these
studies, dexamethasone pretreatment did inhibit the
endotoxin-induced cardiac depression, suggesting
mechanisms other than NO may also be important
in the cardiac dysfunction in the intact heart [91].
NO produced in the heart is derived from both the
expression of iNOS in the vascular and endocardial
endothelium, coronary smooth muscle and cardiac
myocytes and also the constitutive NOS in the cor-
onary endothelium and the endocardium (reviewed
in [5]). In addition to the expression of iNOS, impair-
ment of eNOS in the coronary microvasculature may
also play a role and lead to coronary vasoconstric-
tion and myocardial ischaemia and decreased cardiac
performance. Similarly it is proposed that the re-
duced production of NO from the endothelium
would also enhance adhesion and aggregation of plat-
elets and neutrophil granulocytes (via a reduction in
cGMP) to the intima, possibly leading to further
development of endothelial tissue injury (via oxygen
radical and peroxynitrite-dependent mechanism) [5].
7. NO and liver function in septic shock
It is clearly established that iNOS is induced in the
liver during endotoxic shock [19,30,83,84,92,93].
During sepsis, bacterial products interact with the
Kup¡er cells within the liver to cause the release of
cytokines (IL-1L, IL-6, TNF-K) which interact with
the adjacent hepatocytes to alter parenchymal cell
function, ultimately leading to liver cell damage
and liver failure. The studies of Billiar et al. have
demonstrated that co-cultures of hepatocytes and
Kup¡er cells in the presence of LPS or cultures of
hepatocytes in medium obtained from LPS+IFN-Q-
stimulated Kup¡er cells result in an L-arginine-de-
pendent acute phase reactant synthesis and inhibition
of protein synthesis (reviewed in [93]). This e¡ect is
coincident with the production of NO32 +NO
3
3 , is in-
hibited by L-NMMA and reproduced using synthetic
NO donors, suggesting the involvement of NO. Sub-
sequent studies using both rat and human parenchy-
mal cells have indicated that a mixture of cytokines,
including IL-1L, TNF-K, IFN-Q plus LPS, act syner-
gistically to induce iNOS mRNA and protein, while
LPS alone has no e¡ect [24,93]. A similar inhibition
of albumin synthesis by Kup¡er cell-conditioned me-
dium has also been observed in cultured hepatocytes,
which can be mimicked by a combination of IL-1L,
IL-6 and TNF-K [95]. The mechanism underlying the
e¡ects of NO on protein synthesis remains to be
established; however, it appears to reside at the level
of translation [93].
Hepatic glucose production and hyperglycaemia
are markedly increased in patients with sepsis, insulin
resistance contributing to this process in the hyper-
metabolic phase of sepsis [96]. With overwhelming
sepsis or animals treated with bacterial endotoxin
(hypometabolic phase), an inhibition of hepatic glu-
coneogenesis in the face of elevated peripheral glu-
cose utilisation occurs and hypoglycaemia develops
(reviewed in [6,97]). NO has been implicated as a
possible mediator in the inhibition of gluconeogene-
sis from in vitro [98] and in vivo [99] studies using
arti¢cial NO donors. This is supported by other
studies indicating that the induction of NO synthase
in cultured hepatocytes with a combination of LPS,
IFN-Q, IL-1L and TNF-K coincides with a decreased
rat of glucose formation [24,100^102]. The work of
Stadler et al. [100] indicated that the inhibition of
glucose output (glycogenolysis plus gluconeogenesis)
by this combination of cytokines can be inhibited by
L-NMMA suggesting an involvement of NO; how-
ever, attenuation of the response by NOS inhibitors
has not been found in other studies, either in cul-
tured hepatocytes [24] or hepatocytes freshly pre-
pared from endotoxic rats treated with either L-
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NMMA or aminoguanidine [101]. Similarly the in-
hibition of gluconeogenesis by endotoxin is still evi-
dent in the iNOS de¢cient mouse [101]. A more re-
cent study has indicated that this cytokine
combination results in an inhibition of both glycoge-
nolysis and gluconeogenesis in cultured hepatocytes
and that chronic treatment of the cells with glucagon
attenuates iNOS induction and the inhibition of glu-
cose synthesis [102]. The use of NO synthase inhib-
itors in this study reveals that NO plays an impor-
tant role in the inhibition of glucose output when
cells are stimulated with insulin; however, it makes
a very minor contribution to the inhibition of glucose
synthesis observed in steroid-treated cells. Under the
latter conditions, the formation of reactive oxygen
intermediates is proposed to make the major contri-
bution to the inhibition of glucose output [102],
although a ceramide-dependent inhibition of glucose
output has also been reported which is independent
of NO synthesis [6]. It is postulated that the extent to
which NO is involved in this process is dependent
upon the hormonal milieu and the site(s) at which
metabolic control is exerted within the pathway at
any given time. Recent evidence in favour of the
involvement of NO in the development of hypogly-
caemic phase of sepsis has come from the study of
Ruetten and Thiemermann [38] which demonstrates
that administration of the calpain 1 inhibitor to rats
to prevent IUB degradation prevents both iNOS in-
duction in both lung and liver and also the develop-
ment of the hypoglycaemia characteristic of endotox-
in treatment.
A signi¢cant feature of septic or endotoxic shock
is hepatocellular failure and liver damage, with the
release of aspartate aminotransferase, ornithine car-
bamoyl transferase and lactate dehydrogenase into
the bloodstream as seen in the onset of MODS. A
number of studies have implicated NO as a contrib-
uting factor to liver damage by employing in vivo
treatment of animals with NOS inhibitors; however,
the precise role for NO has been di⁄cult to deter-
mine because of the use of non-speci¢c NO synthase
inhibitors. Billiar et al. have demonstrated that in the
C. parvum plus LPS murine model of endotoxic
shock, a bolus injection of L-NMMA together with
the LPS prevents NO formation; however, it sub-
stantially exacerbates the endotoxin-induced liver in-
jury [93]. The liver damage is associated with in-
creased numbers of microinfarcts and platelet
thrombi within the small vessels and it has been sug-
gested that inhibition of NO synthesis causes disturb-
ances of blood £ow resulting from platelet adhesion
and aggregation, vasoconstriction, clot formation
and subsequent ischaemia with O32 production. In
these studies, the e¡ect of L-NMMA was exaggerated
by the presence of aspirin, suggesting that NO and
prostacyclins act together to maintain hepatic blood
£ow during sepsis, whereas it is abrogated by co-
administration of superoxide dismutase or deferrox-
amine, suggesting that NO may also function by pre-
venting damage by reactive oxygen radicals ([93] and
references therein). A more recent study employing
infusion of a combination of either non-speci¢c or
more iNOS-selective inhibitors together with LPS
has con¢rmed that the non-selective inhibitors lead
to an exacerbation of liver damage and an increase in
LPS-induced necrosis [94]. The increased necrosis is
associated with, but independent of increased ICAM-
1 expression and neutrophil migration into the liver.
Co-infusion of O2-vinyl 1-(pyrrolidin-1-yl)diazen-1-
ium-1,2-diolate (V-PYRRO/NO) to deliver exoge-
nous NO at the level of the liver reversed the e¡ects
of the non-selective NOS inhibitors, con¢rming a
protective e¡ect of NO. V-PYRRO/NO infusion
did not inhibit the basal LPS-induced damage indi-
cative of the involvement of non-NO mediated mech-
anisms [94], which is supported by the ¢nding that
liver injury is also a feature of the iNOS-de¢cient
mouse following treatment with LPS [29]. In the
study of Ou et al. speci¢c iNOS inhibition did not
a¡ect liver necrosis, ICAM-1 expression or neutro-
phil in¢ltration suggesting that NO produced by
eNOS has the major protective role in limiting in-
£ammation-induced tissue damage. In contrast to
the above study, a model using a bolus injection of
selective iNOS inhibitors has suggested that overpro-
duction of NO by iNOS may also play a signi¢cant
role in inducing hepatic damage and MODS in ro-
dent models of endotoxic shock (reviewed in [4]).
These inhibitors, based upon substituted guanidines
or isothiurea derivatives, have been shown to attenu-
ate liver dysfunction, under conditions where L-
NMMA exacerbated hepatic damage. In support of
this, prevention of IUB degradation by the calpain 1
inhibitor or blocking NF-UB activation with dexame-
thasone to prevent iNOS induction attenuates the
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onset of MODS and liver damage in the rat model of
endotoxic shock further strengthening the role of en-
hanced NO formation by iNOS being detrimental
[38]. However, other mechanisms in addition to
iNOS induction cannot be completely eliminated us-
ing this approach as the induction of other proteins
such as COX-2 which are also induced via an NF-
UB-dependent mechanism would also be inhibited.
Although the extent of the involvement of iNOS in
causing liver necrosis is unclear, it is evident that it is
the inhibition of the constitutive eNOS and not
iNOS which exacerbates the LPS-induced liver dam-
age in studies employing non-speci¢c NOS inhibi-
tors. It is likely that in reality liver damage and
MODS are actually a combination of excessive
NO, alterations in liver perfusion as a result of dis-
turbances in the hepatic microcirculation and the
generation and interaction of other factors with
NO, e.g. reactive oxygen intermediates.
A similar situation to that in liver has also been
observed in the rat small intestine. Induction of
iNOS following in vivo endotoxin challenge is asso-
ciated with a reduction in cell viability, mitochon-
drial dysfunction, vasocongestion and plasma exuda-
tion into the intestinal lumen [103^105]. Pretreatment
with L-NMMA prevents NO formation; however, it
enhances the endotoxin-induced intestinal damage
and plasma leak [104], while NO donors attenuate
this damage [106]. Inhibition of iNOS induction by
pretreatment with dexamethasone or speci¢c inhibi-
tion of NO formation with selective iNOS inhibitors
also results in attenuation of cell damage, mitochon-
drial dysfunction and intestinal hyperpermeability
[103,105], suggesting that NO formed by the constit-
utive enzyme aids in the maintenance of microvascu-
lar £ow and epithelial cell integrity, while excessive
NO production due to iNOS contributes to cell dam-
age and accumulation of £uid within the intestinal
lumen [103,105].
8. NO and apoptosis in septic shock
In addition to death by necrosis, cells may also
undergo programmed cell death or apoptosis. Apop-
tosis and DNA fragmentation have been demon-
strated in a variety of tissues following endotoxin
treatment of the rat, including liver, lung, kidneys,
thymocytes and intestine [107,108], although in the
liver of non-sensitised animals this occurs in a very
small proportion of cells [94,107]. The importance of
NO in apoptosis is complex and outside the scope of
this review; however, NO has been shown to sup-
press apoptosis in a number of cell types including
endothelial cells, lymphocytes, eosinophils and hep-
atocytes, whereas it has been shown to induce apop-
tosis in macrophages, L-cells and thymocytes (re-
viewed in [109]). The ultimate e¡ect of NO is likely
to depend upon the tissue type, source and concen-
tration of NO and duration of treatment [109]. Re-
cent studies in liver have demonstrated that signi¢-
cant apoptosis only occurs when LPS is infused
together with a NOS inhibitor [94]. This can be pre-
vented by simultaneous administration of the liver-
speci¢c NO donor, V-PYRRO/NO, indicative of a
protective role of NO. In contrast to necrosis,
iNOS-speci¢c inhibitors are equally potent with
non-speci¢c inhibitors in inducing apoptosis, suggest-
ing that the inhibition of apoptosis is the result of
iNOS expression in the liver or a combination of
both iNOS and eNOS activity [94]. The mechanisms
underlying the e¡ects of NO on apoptosis remain to
be fully elucidated. NO appears to be able to protect
cells from apoptosis by several mechanisms. Large
quantities of NO generated by iNOS protect from
TNF-K-induced apoptosis by induction of heat shock
protein 70, whereas small quantities block via mech-
anisms involving inhibition of caspase-3-like protease
activation, possibly via S-nitrosylation of the protein
([94,109] and references therein). In contrast, the in-
duction of apoptosis by high concentrations of NO
may re£ect direct DNA damage in the susceptible
tissues [109].
9. Conclusion
In conclusion, it is evident that excessive produc-
tion of NO following the induction of iNOS as a
result of an increased circulating cytokine concentra-
tion makes a major contribution to the development
of the characteristic symptoms of septic or endotoxic
shock. However, it is evident that in many cases an
increase in NO by itself may be insu⁄cient, and the
generation of other mediators, e.g. reactive oxygen
intermediates, may also play a crucial role in the
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tissue dysfunction and damage observed in septic
shock and MODS. Indeed NO produced by both
eNOS and in some cases iNOS may be bene¢cial
and ameliorate the tissue damage and apoptosis as-
sociated with septic shock. Much of our knowledge
concerning the involvement of NO has been derived
from isolated cell or tissue systems (frequently using
rodent tissue and rodent models of shock), and the
use of non-speci¢c inhibitors of NO synthases.
Although these produce useful insights into the phys-
iological situation in man, extrapolation of the data
needs to be approached with some caution. For ex-
ample, in vitro experiments rarely take into account
the interplay with the e¡ects of counter-regulatory
factors which are also elevated during septic shock,
e.g. increased circulating concentrations of cytokines
(IL-10, TGF-L), steroid hormones and cAMP medi-
ated hormones (glucagon and catecholamines), while
rodent tissue is relatively insensitive to endotoxin and
cytokines, relative to that of humans [5]. Similarly
the use of non-speci¢c NO synthase inhibitors has
led to contradictory interpretations because of the
inhibition of both the constitutive and inducible
forms of NOS. With the development and increased
availability of iNOS speci¢c inhibitors, this problem
should be resolved and the results from clinical trials
employing these agents should allow us to better
understand the role of excessive NO production in
shock in man.
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